Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response
Open accessThe DOI matches its Crossref record; 64 of the 70 references it cites were found in a registry or an index, and 6 are not checked yet; 19 of the 29 sources its claims cite were checked for support.
Abstract
Another benefit of dietary fiber: The gut microbiome can modulate the immune system and influence the therapeutic response of cancer patients, yet the mechanisms underlying the effects of microbiota are presently unclear. Spencer et al . add to our understanding of how dietary habits affect microbiota and clinical outcomes to immunotherapy. In an observational study, the researchers found that melanoma patients reporting high fiber (prebiotic) consumption had a better response to checkpoint inhibitor immunotherapy compared with those patients reporting a low-fiber diet. The most marked benefit was observed for those patients reporting a combination of high fiber consumption and no use of over-the-counter probiotic supplements. These findings provide early insights as to how diet-related factors may influence the immune response. —PNK
Verified 2026-10-05 · 6 references not checked yet
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 0 Not valid · 3 Not checked · 41 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Gut bacteria modulate the response to immune checkpoint blockade (ICB) treatment in cancer”
§ Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response > Abstract
What the sources say
- Not checked yetcites [2] Routy B, Science 359, 91– 97 (2018). 29097494 source
- Supportedcites [3] Matson V, Science 359, 104– 108 (2018). 29302014 PMC6707353 source
The supplied Abstract passage reports an association between gut microbial composition and clinical response to anti-PD-1 therapy in metastatic melanoma patients. It also reports that transferring responder-associated microbiota improved anti-PD-L1 efficacy in mice, supporting the claim that gut bacteria can modulate response to checkpoint blockade. (LLM, conf=0.91)
- Partly supportedcites [4] Gopalakrishnan V, Science 359, 97– 103 (2018). 29097493 PMC5827966 sourceExperimental — accuracy not yet measured
The paper’s concluding passage says the gut microbiome may modulate responses to anti-PD-1 immunotherapy in melanoma patients. The citing sentence states this more broadly and definitively for immune checkpoint blockade in cancer; the paper’s patient findings are limited to melanoma and anti-PD-1 treatment. Page numbers were not provided in our copy. (LLM, conf=0.85)
- Partly supportedcites [5] Frankel AE, Neoplasia 19, 848– 855 (2017). 28923537 PMC5602478 sourceExperimental — accuracy not yet measured
The Introduction reports that gut microbiota affect checkpoint-therapy responses in preclinical mouse models, and the Results find different bacterial species enriched in melanoma patients who responded to treatment. The human findings are associations, however; the paper says the mechanism of immune enhancement by these bacteria in humans remains unknown. Thus it does not establish that gut bacteria modulate treatment response in cancer patients. (LLM, conf=0.84)
- Supportedcites [6] Peters BA, Genome Med 11, 61 (2019). 31597568 PMC6785875 source
The Conclusions state that the pilot study supports the notion that gut microbiota modulate immunotherapy response in melanoma patients. The Background identifies the treatments studied as PD-1 and CTLA-4 checkpoint inhibitors, matching the claim’s reference to immune checkpoint blockade. (LLM, conf=0.91)
- Partly supportedcites [7] Andrews MC, Nat. Med 27, 1432– 1441 (2021). 34239137 PMC11107795 sourceExperimental — accuracy not yet measured
The Main Text reports that several gut bacterial taxa differed between melanoma patients who did and did not respond to combined checkpoint blockade, with related associations in mouse tumor models (page unavailable). This supports a link between gut bacteria and treatment response, but the patient findings are associations; they do not establish that bacteria modulate response in cancer patients generally. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“given the known impact of these on ICB response (32)”
§ Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response > Abstract
What the sources say
- Partly supportedcites [32] Pinato DJ, JAMA Oncol 5, 1774– 1778 (2019). 31513236 PMC6743060 sourceExperimental — accuracy not yet measured
The Key Points report that antibiotics given within 30 days before immune checkpoint inhibitor therapy were associated with a higher risk of disease refractory to treatment. The claim is broader than the finding: the paper reports an observational association for prior antibiotic use, while its Limitations section says concurrent antibiotic use was not associated with response. (LLM, conf=0.86)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“however, this is not unexpected given the known challenges of isolating associations of specific dietary components from other factors known to affect the gut microbiota in observational human cohorts (33, 34).”
§ Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response > Abstract
What the sources say
- Supportedcites [33] Klurfeld DM, Am. J. Physiol. Endocrinol. Metab 315, E1087– E1097 (2018). 30130151 PMC6415710 source
The WORKSHOP SUMMARY ('Focus on human studies of the colonic microbiome') states numerous challenges in characterizing diet effects on the human gut microbiome, including poor adherence, inaccurate characterization of dietary intake/composition, and that human observational studies generally point only to associations, with logistical challenges in large cohort studies. The same summary notes that diets high in protein or fat are necessarily low in carbohydrates, 'making it almost impossible to attribute causality to an individual macronutrient,' and lists nondietary factors (stress, exercise, smoking, coffee, personality) plus marked interindividual variation that must be recorded. The table under 'Choice of species depends on question(s) asked.' adds that cross-sectional studies cannot prove causality and that intake recording is relatively inaccurate. Together these support the paraphrase that isolating specific dietary components from other microbiota-affecting factors in observational human cohorts is challenging. (LLM, conf=0.87)
- Not checked yetcites [34] Makki K, Deehan EC, Walter J, Bäckhed F, Cell Host Microbe 23, 705– 715 (2018). 29902436 source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Given that many of the response-associated bacteria identified in our cohort have known roles in starch degradation and fiber fermentation (25–29)”
§ Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response > Abstract
What the sources say
- Supportedcites [25] Flint HJ, Scott KP, Duncan SH, Louis P, Forano E, Gut Microbes 3, 289– 306 (2012). 22572875 PMC3463488 source
The paper’s Firmicutes sections describe starch utilization by Roseburia and Eubacterium rectale and plant-fiber polysaccharide utilization by Roseburia intestinalis and other gut bacteria (page numbers unavailable). The citation supports the bacteria’s known roles; identifying which bacteria were response-associated in the citing authors’ cohort is the citing authors’ own observation. (LLM, conf=0.86)
- Partly supportedcites [26] den Besten G, J. Lipid Res 54, 2325– 2340 (2013). 23821742 PMC3735932 sourceExperimental — accuracy not yet measured
In “The composition of gut microbiota” (page unavailable), the review identifies Bacteroidetes as fermenters of nondigestible carbohydrates, supporting a general role for gut bacteria in fiber fermentation. It does not identify the citing paper’s response-associated bacteria or establish that many of them degrade starch. (LLM, conf=0.84)
- Partly supportedcites [27] Poeker SA, Sci. Rep 8, 4318 (2018). 29531228 PMC5847601 sourceExperimental — accuracy not yet measured
The Results and Discussion describe bacterial responses to dietary fibers and identify taxa involved in fermenting or degrading them, including inulin-degrading Ruminococcaceae and Prevotella fermenting complex polysaccharides. The paper does not establish a role in starch degradation for these bacteria. Which bacteria were identified in the citing authors’ cohort is their own finding, not a finding attributed to this source. (LLM, conf=0.84)
- Partly supportedcites [28] So D, Am. J. Clin. Nutr 107, 965– 983 (2018). 29757343 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says Bifidobacterium and Lactobacillus utilize prebiotic fibers as substrates and discusses their fermentation preferences, supporting the fiber-fermentation part. The paper does not establish starch-degradation roles for many bacteria; its References list a work on Ruminococcus bromii and resistant-starch degradation, but that does not substantiate the broader claim. (LLM, conf=0.82)
- Supportedcites [29] Desai MS, Cell 167, 1339– 1353. e21 (2016). 27863247 PMC5131798 source
The Results describe testing gut bacteria for growth on dietary-fiber polysaccharides and identifying which bacteria use each carbohydrate. The supplemental figure (Additional information; page unavailable) identifies several species as plant-fiber and starch degraders and depicts short-chain fatty acid production from plant fiber. The cited paper supports those functional roles; the statement that the bacteria were response-associated in the citing authors’ cohort is their own framing. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The observed protective effect of dietary fiber intake in relation to PFS and response remained consistent among the subset of patients treated with anti–PD-1 monotherapy, with the exclusion of patients reporting recent antibiotic use given the known impact of these on ICB response (32) (tables S11 and S12).”
§ Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response > Abstract
What the sources say
- Supportedcites [32] Pinato DJ, JAMA Oncol 5, 1774– 1778 (2019). 31513236 PMC6743060 source
The citation is attached to the rationale for excluding patients with recent antibiotic use, not to the citing authors’ dietary-fiber findings. The Results report that prior antibiotic therapy was associated with poorer response to immune checkpoint inhibitor treatment; the paper distinguishes this from concurrent antibiotic therapy. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
33 more claims · 1 with their cited sources checked
Create a free account to see all 52 claims and to verify the 10 references still open.
- Probably not a substantial claim. 8
- It may state two separate claims as one. 7
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fiber-rich, plant-based diets have the opposite effect, nurturing Bifidobacterium and Lactobacillus, increasing butyrate producers like Roseburia and Eubacterium rectale, and shielding against obesity and insulin resistance via SCFA signaling.15,70,81–83”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical studies have linked deficient SCFA production to conditions such as graft-versus-host disease and poor responses to cancer immunotherapies, spurring interest in SCFA supplementation or diets to restore microbial balance.15,77,88,146,147”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“supporting a potential benefit of microbially produced SCFAs and an adjuvant role of fiber for ICB7,25.”
From Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“First, correlations have been drawn across cancer indications and geographical sites between the taxonomic composition of the gut (and to some degree tumor) microbiota, and ICI responses in patients with melanoma and other cancers.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Second, exposures including medications, especially antibiotics and proton pump inhibitors, and diet that shape the microbiota are associated with ICI responses in patient cohorts and preclinical models.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [13]
Experimental — accuracy not yet measured
28 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Fitting Linear Mixed-Effects Models Using lme4
Bates, D., Mächler, M., Bolker, B., & Walker, S. (2015) · Journal of Statistical Software · doi:10.18637/jss.v067.i01 · Cited by 86,835
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Cytoscape: A software Environment for integrated models of biomolecular interaction networks
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888
DADA2: High–resolution sample inference from Illumina amplicon data
Callahan, B. J., McMurdie, P. J., Rosen, M. J., Han, A. W., Johnson, A. J. A., & Holmes, S. P. (2016) · Nature Methods · doi:10.1038/nmeth.3869 · Cited by 35,698
QIIME allows analysis of high-throughput community sequencing data
Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., Fierer, N., Peña, A. G., Goodrich, J. K., Gordon, J. I., et al. (2010) · Nature Methods · doi:10.1038/nmeth.f.303 · Cited by 34,887
The SILVA ribosomal RNA gene database project: improved data processing and web-based tools
Quast, C., Pruesse, E., Yilmaz, P., Gerken, J., Schweer, T., Yarza, P., Peplies, J., & Glöckner, F. O. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1219 · Cited by 33,055
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
lmerTest Package: Tests in Linear Mixed Effects Models
Kuznetsova, A., Brockhoff, P. B., & Christensen, R. H. B. (2017) · Journal of Statistical Software · doi:10.18637/jss.v082.i13 · Cited by 24,346
Naïve Bayesian Classifier for Rapid Assignment of rRNA Sequences into the New Bacterial Taxonomy
Wang, Q., Garrity, G. M., Tiedje, J. M., & Cole, J. R. (2007) · Applied and Environmental Microbiology · doi:10.1128/aem.00062-07 · Cited by 19,885
Schloss, P. D., Westcott, S. L., Ryabin, T., Hall, J. R., Hartmann, M., Hollister, E. B., Lesniewski, R. A., Oakley, B. B., Parks, D. H., Robinson, C. J., et al. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.01541-09 · Cited by 19,549
Research works printed but not linked: 1
- H. Mallick A. Rahnavard L. J. McIver S. Ma Y. Zhang L. H. Nguyen T. L. Tickle G. Weingart B. Ren E. H. Schwager S. Chatterjee K. N. Thompson J. E. Wilkinson A. Subramanian Y. Lu L. Waldron J. N. Paulson E. A. Franzosa H. C. Bravo C. Huttenhower Multivariable Association Discovery in Population-scale Meta-omics Studies. bioRxiv 2021.01.20.427420 [Preprint] (2021). .10.1101/2021.01.20.427420 2021.01.20.427420 · doi:10.1101/2021.01.20.427420
Cited by
Immune checkpoint therapy—current perspectives and future directions
Sharma, P., Goswami, S., Raychaudhuri, D., Siddiqui, B. A., Singh, P., Nagarajan, A., Liu, J., Subudhi, S. K., Poon, C., Gant, K. L., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.006 · Cited by 1,206
Self-citationClinical relevance of tumour-associated macrophages
Pittet, M. J., Michielin, O., & Migliorini, D. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00620-6 · Cited by 731
Bender, M. J., McPherson, A. C., Phelps, C. M., Pandey, S. P., Laughlin, C. R., Shapira, J. H., Medina Sanchez, L., Rana, M., Richie, T. G., Mims, T. S., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.011 · Cited by 732
“17 Thus, the impact of probiotics on ICI responsiveness in cancer patients, as well as the mechanisms that drive these effects, remain poorly understood.”
InfluentialSelf-citationGut microbiota in colorectal cancer development and therapy
Wong, C. C., & Yu, J. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00766-x · Cited by 721
Microbiota and maintenance of skin barrier function
Harris-Tryon, T. A., & Grice, E. A. (2022) · Science · doi:10.1126/science.abo0693 · Cited by 651
Faecalibacterium: a bacterial genus with promising human health applications
Martín, R., Rios-Covian, D., Huillet, E., Auger, S., Khazaal, S., Bermúdez-Humarán, L. G., Sokol, H., Chatel, J.-M., & Langella, P. (2023) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuad039 · Cited by 566
Embracing cancer complexity: Hallmarks of systemic disease
Swanton, C., Bernard, E., Abbosh, C., André, F., Auwerx, J., Balmain, A., Bar-Sagi, D., Bernards, R., Bullman, S., DeGregori, J., et al. (2024) · Cell · doi:10.1016/j.cell.2024.02.009 · Cited by 540
Self-citationFecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
Routy, B., Lenehan, J. G., Miller, W. H., Jamal, R., Messaoudene, M., Daisley, B. A., Hes, C., Al, K. F., Martinez-Gili, L., Punčochář, M., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02453-x · Cited by 526
Targeting the gut and tumor microbiota in cancer
Park, E. M., Chelvanambi, M., Bhutiani, N., Kroemer, G., Zitvogel, L., & Wargo, J. A. (2022) · Nature Medicine · doi:10.1038/s41591-022-01779-2 · Cited by 496
Self-citationMicrobiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer
Tintelnot, J., Xu, Y., Lesker, T. R., Schönlein, M., Konczalla, L., Giannou, A. D., Pelczar, P., Kylies, D., Puelles, V. G., Bielecka, A. A., et al. (2023) · Nature · doi:10.1038/s41586-023-05728-y · Cited by 478
A pan-cancer mycobiome analysis reveals fungal involvement in gastrointestinal and lung tumors
Dohlman, A. B., Klug, J., Mesko, M., Gao, I. H., Lipkin, S. M., Shen, X., & Iliev, I. D. (2022) · Cell · doi:10.1016/j.cell.2022.09.015 · Cited by 413
Altmann, D. M., Whettlock, E. M., Liu, S., Arachchillage, D. J., & Boyton, R. J. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00904-7 · Cited by 389
Gangavarapu, K., Latif, A. A., Mullen, J. L., Alkuzweny, M., Hufbauer, E., Tsueng, G., Haag, E., Zeller, M., Aceves, C. M., Zaiets, K., et al. (2023) · Nature Methods · doi:10.1038/s41592-023-01769-3 · Cited by 394
γδ T cells: origin and fate, subsets, diseases and immunotherapy
Hu, Y., Hu, Q., Li, Y., Lu, L., Xiang, Z., Yin, Z., Kabelitz, D., & Wu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01653-8 · Cited by 382
Probiotics, prebiotics, and postbiotics in health and disease
Ji, J., Jin, W., Liu, S., Jiao, Z., & Li, X. (2023) · MedComm · doi:10.1002/mco2.420 · Cited by 384
Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications
Zhao, L.-Y., Mei, J.-X., Yu, G., Lei, L., Zhang, W.-H., Liu, K., Chen, X.-L., Kołat, D., Yang, K., & Hu, J.-K. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01406-7 · Cited by 359
Self-citationBacteria in cancer initiation, promotion and progression
El Tekle, G., & Garrett, W. S. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00594-2 · Cited by 343
Self-citationTargeting gut microbiota and metabolism as the major probiotic mechanism - An evidence-based review
Ma, T., Shen, X., Shi, X., Sakandar, H. A., Quan, K., Li, Y., Jin, H., Kwok, L.-Y., Zhang, H., & Sun, Z. (2023) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2023.06.013 · Cited by 329
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours
Holder, A. M., Dedeilia, A., Sierra-Davidson, K., Cohen, S., Liu, D., Parikh, A., & Boland, G. M. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00705-7 · Cited by 298
Linoleic acid potentiates CD8+ T cell metabolic fitness and antitumor immunity
Nava Lauson, C. B., Tiberti, S., Corsetto, P. A., Conte, F., Tyagi, P., Machwirth, M., Ebert, S., Loffreda, A., Scheller, L., Sheta, D., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.02.013 · Cited by 291
Self-citationTargeting the gut microbiota for cancer therapy
Fernandes, M. R., Aggarwal, P., Costa, R. G. F., Cole, A. M., & Trinchieri, G. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00513-x · Cited by 290
Self-citationLipid metabolism in T cell signaling and function
Lim, S. A., Su, W., Chapman, N. M., & Chi, H. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-01017-3 · Cited by 278
Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes
Ting, N. L.-N., Lau, H. C.-H., & Yu, J. (2022) · Gut · doi:10.1136/gutjnl-2021-326264 · Cited by 274
Mechanisms driving the immunoregulatory function of cancer cells
van Weverwijk, A., & de Visser, K. E. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00544-4 · Cited by 272
Colbert, L. E., El Alam, M. B., Wang, R., Karpinets, T., Lo, D., Lynn, E. J., Harris, T. A., Elnaggar, J. H., Yoshida-Court, K., Tomasic, K., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.09.012 · Cited by 270
Self-citationIntratumoural microbiota: a new frontier in cancer development and therapy
Cao, Y., Xia, H., Tan, X., Shi, C., Ma, Y., Meng, D., Zhou, M., Lv, Z., Wang, S., & Jin, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01693-0 · Cited by 253
Simpson, R. C., Shanahan, E. R., Batten, M., Reijers, I. L. M., Read, M., Silva, I. P., Versluis, J. M., Ribeiro, R., Angelatos, A. S., Tan, J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01965-2 · Cited by 256
Self-citationA Review of Gut Microbiota‐Derived Metabolites in Tumor Progression and Cancer Therapy
Yang, Q., Wang, B., Zheng, Q., Li, H., Meng, X., Zhou, F., & Zhang, L. (2023) · Advanced Science · doi:10.1002/advs.202207366 · Cited by 240
Role of gut microbiota in infectious and inflammatory diseases
Maciel-Fiuza, M. F., Muller, G. C., Campos, D. M. S., do Socorro Silva Costa, P., Peruzzo, J., Bonamigo, R. R., Veit, T., & Vianna, F. S. L. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1098386 · Cited by 233
Current and future immunotherapeutic approaches in pancreatic cancer treatment
Farhangnia, P., Khorramdelazad, H., Nickho, H., & Delbandi, A.-A. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01561-6 · Cited by 229
An integrated tumor, immune and microbiome atlas of colon cancer
Roelands, J., Kuppen, P. J. K., Ahmed, E. I., Mall, R., Masoodi, T., Singh, P., Monaco, G., Raynaud, C., de Miranda, N. F. C. C., Ferraro, L., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02324-5 · Cited by 213
Effects of dietary intervention on human diseases: molecular mechanisms and therapeutic potential
Xiao, Y.-L., Gong, Y., Qi, Y.-J., Shao, Z.-M., & Jiang, Y.-Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01771-x · Cited by 202
Derosa, L., Iebba, V., Silva, C. A. C., Piccinno, G., Wu, G., Lordello, L., Routy, B., Zhao, N., Thelemaque, C., Birebent, R., et al. (2024) · Cell · doi:10.1016/j.cell.2024.05.029 · Cited by 198
Targeting PD-L2–RGMb overcomes microbiome-related immunotherapy resistance
Park, J. S., Gazzaniga, F. S., Wu, M., Luthens, A. K., Gillis, J., Zheng, W., LaFleur, M. W., Johnson, S. B., Morad, G., Park, E. M., et al. (2023) · Nature · doi:10.1038/s41586-023-06026-3 · Cited by 191
Self-citationDiets intervene osteoporosis via gut-bone axis
Zhang, Y.-W., Song, P.-R., Wang, S.-C., Liu, H., Shi, Z.-M., & Su, J.-C. (2024) · Gut Microbes · doi:10.1080/19490976.2023.2295432 · Cited by 176
Dietary regulation in health and disease
Wu, Q., Gao, Z.-J., Yu, X., & Wang, P. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01104-w · Cited by 176
Critical role of the gut microbiota in immune responses and cancer immunotherapy
Li, Z., Xiong, W., Liang, Z., Wang, J., Zeng, Z., Kołat, D., Li, X., Zhou, D., Xu, X., & Zhao, L. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01541-w · Cited by 176
Utilization of the microbiome in personalized medicine
Ratiner, K., Ciocan, D., Abdeen, S. K., & Elinav, E. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00998-9 · Cited by 170
A gut microbial signature for combination immune checkpoint blockade across cancer types
Gunjur, A., Shao, Y., Rozday, T., Klein, O., Mu, A., Haak, B. W., Markman, B., Kee, D., Carlino, M. S., Underhill, C., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02823-z · Cited by 165
Halsey, T. M., Thomas, A. S., Hayase, T., Ma, W., Abu-Sbeih, H., Sun, B., Parra, E. R., Jiang, Z.-D., DuPont, H. L., Sanchez, C., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abq4006 · Cited by 161
Self-citationModulating gut microbiome in cancer immunotherapy: Harnessing microbes to enhance treatment efficacy
Kang, X., Lau, H. C.-H., & Yu, J. Q. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101478 · Cited by 197
Gut Microbiota-Derived Short-Chain Fatty Acids: Impact on Cancer Treatment Response and Toxicities
Al-Qadami, G. H., Secombe, K. R., Subramaniam, C. B., Wardill, H. R., & Bowen, J. M. (2022) · Microorganisms · doi:10.3390/microorganisms10102048 · Cited by 162
Gut microbiota shapes cancer immunotherapy responses
Lei, W., Zhou, K., Lei, Y., Li, Q., & Zhu, H. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00786-8 · Cited by 194
Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors
Simpson, R. C., Shanahan, E. R., Scolyer, R. A., & Long, G. V. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00803-9 · Cited by 153
Nutritional regulation of microbiota-derived metabolites: Implications for immunity and inflammation
Arifuzzaman, M., Collins, N., Guo, C., & Artis, D. (2024) · Immunity · doi:10.1016/j.immuni.2023.12.009 · Cited by 168
Vitamin D regulates microbiome-dependent cancer immunity
Giampazolias, E., Pereira da Costa, M., Lam, K. C., Lim, K. H. J., Cardoso, A., Piot, C., Chakravarty, P., Blasche, S., Patel, S., Biram, A., et al. (2024) · Science · doi:10.1126/science.adh7954 · Cited by 151
Self-citationLongitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma
Björk, J. R., Bolte, L. A., Maltez Thomas, A., Lee, K. A., Rossi, N., Wind, T. T., Smit, L. M., Armanini, F., Asnicar, F., Blanco-Miguez, A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02803-3 · Cited by 156
Self-citationButyrate as a promising therapeutic target in cancer: From pathogenesis to clinic (Review)
Sun, J., Chen, S., Zang, D., Sun, H., Sun, Y., & Chen, J. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5632 · Cited by 165
Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy
Thomas, A. M., Fidelle, M., Routy, B., Kroemer, G., Wargo, J. A., Segata, N., & Zitvogel, L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00785-8 · Cited by 141
Self-citationRole of the microbiota in response to and recovery from cancer therapy
Blake, S. J., Wolf, Y., Boursi, B., & Lynn, D. J. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00951-0 · Cited by 158
Diet fuelling inflammatory bowel diseases: preclinical and clinical concepts
Adolph, T. E., & Zhang, J. (2022) · Gut · doi:10.1136/gutjnl-2021-326575 · Cited by 160
Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target
Zhang, M., Liu, J., & Xia, Q. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00442-x · Cited by 167
Small intestine vs. colon ecology and physiology: Why it matters in probiotic administration
Jensen, B. A. H., Heyndrickx, M., Jonkers, D. M. A. E., Mackie, A. R., Millet, S., Naghibi, M., Pærregaard, S. I., Pot, B., Saulnier, D. M. A., Sina, C., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101190 · Cited by 188
Xu, L., Zhang, Y., Li, X., Li, C., Hu, H., Hu, J., Liu, M., Yang, Q. Z., Gu, P., Li, J., et al. (2025) · iMeta · doi:10.1002/imt2.270 · Cited by 153
Self-citationNeuro-immune crosstalk in cancer: mechanisms and therapeutic implications
Pu, T., Sun, J., Ren, G., & Li, H. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02241-8 · Cited by 171
Advancing CAR T cell therapy through the use of multidimensional omics data
Yang, J., Chen, Y., Jing, Y., Green, M. R., & Han, L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00729-2 · Cited by 135
Beyond the Barrier: Unraveling the Mechanisms of Immunotherapy Resistance
Bell, H. N., & Zou, W. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101819-024752 · Cited by 149
Immune-checkpoint inhibitor resistance in cancer treatment: Current progress and future directions
Zhang, C., Zhang, C., & Wang, H. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216182 · Cited by 127
Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?
Ziogas, D. C., Theocharopoulos, C., Koutouratsas, T., Haanen, J. B. A. G., & Gogas, H. J. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102499 · Cited by 129
Gao, Y., Xu, P., Sun, D., Jiang, Y., Lin, X.-L., Han, T., Yu, J., Sheng, C., Chen, H., Hong, J., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0605 · Cited by 116
The gut microbiome and cancer: from tumorigenesis to therapy
Nobels, A., van Marcke, C., Jordan, B. F., Hul, M. V., & Cani, P. D. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01287-w · Cited by 136
Ebrahimi, H., Dizman, N., Meza, L., Malhotra, J., Li, X., Dorff, T., Frankel, P., Llamas-Quitiquit, M., Hsu, J., Zengin, Z. B., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03086-4 · Cited by 109
Bolte, L. A., Lee, K. A., Björk, J. R., Leeming, E. R., Campmans-Kuijpers, M. J. E., de Haan, J. J., Vila, A. V., Maltez-Thomas, A., Segata, N., Board, R., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2022.7753 · Cited by 106
The gut microbiome and dietary fibres: implications in obesity, cardiometabolic diseases and cancer
Delzenne, N. M., Bindels, L. B., Neyrinck, A. M., & Walter, J. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-024-01108-z · Cited by 125
The Benefits and Safety of Monoclonal Antibodies: Implications for Cancer Immunotherapy
Zhang, S., Chen, W., Zhou, J., Liang, Q., Zhang, Y., Su, M., Zhang, Z., & Qu, J. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s499403 · Cited by 128
Newsome, R. C., Gharaibeh, R. Z., Pierce, C. M., da Silva, W. V., Paul, S., Hogue, S. R., Yu, Q., Antonia, S., Conejo-Garcia, J. R., Robinson, L. A., et al. (2022) · Genome Medicine · doi:10.1186/s13073-022-01037-7 · Cited by 104
Urea cycle activation triggered by host-microbiota maladaptation driving colorectal tumorigenesis
Chen, H., Tong, T., Lu, S., Ji, L., Xuan, B., Zhao, G., Yan, Y., Song, L., Zhao, L., Xie, Y., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.03.003 · Cited by 112
Self-citationAghamajidi, A., & Vareki, S. M. (2022) · Cancers · doi:10.3390/cancers14153563 · Cited by 110
Xu, H., Cao, C., Ren, Y., Weng, S., Liu, L., Guo, C., Wang, L., Han, X., Ren, J., & Liu, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.949490 · Cited by 126
Self-citationTomita, Y., Goto, Y., Sakata, S., Imamura, K., Minemura, A., Oka, K., Hayashi, A., Jodai, T., Akaike, K., Anai, M., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2081010 · Cited by 100
Spreafico, A., Heirali, A. A., Araujo, D. V., Tan, T. J., Oliva, M., Schneeberger, P. H. H., Chen, B., Wong, M. K., Stayner, L.-A., Hansen, A. R., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.02.011 · Cited by 96
Self-citationBoosting Checkpoint Immunotherapy with Biomaterials
Liu, L., Pan, Y., Zhao, C., Huang, P., Chen, X. S., & Rao, L. (2023) · ACS Nano · doi:10.1021/acsnano.2c11691 · Cited by 100
Targeted modification of gut microbiota and related metabolites via dietary fiber
Nie, Q., Sun, Y., Li, M., Zuo, S., Chen, C., Lin, Q., & Nie, S. (2023) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2023.120986 · Cited by 101
Turning cold tumors into hot tumors to ignite immunotherapy
Liu, Y., Wang, Y., Wang, S., Li, J., He, W. A., Fan, X.-J., & Wan, X. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02477-6 · Cited by 135
Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies
Xie, J., Liu, M., Deng, X., Tang, Y., Zheng, S., Ou, X., Tang, H., Xie, X., Wu, M., & Zou, Y. (2024) · iMeta · doi:10.1002/imt2.156 · Cited by 108
Clinical translation of microbiome research
Gilbert, J. A., Azad, M. B., Bäckhed, F., Blaser, M. J., Byndloss, M. X., Chiu, C. Y., Chu, H., Dugas, L. R., Elinav, E., Gibbons, S. M., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03615-9 · Cited by 123
Phelps, C. M., Willis, N. B., Duan, T., Lee, A. H., Zhang, Y., Rodriguez J, D. M., Pandey, S. P., Laughlin, C. R., Rosen, A. B. I., McPherson, A. C., et al. (2025) · Cell · doi:10.1016/j.cell.2025.06.018 · Cited by 91
Self-citationInamura, K., Hamada, T., Bullman, S., Ugai, T., Yachida, S., & Ogino, S. (2022) · Gut · doi:10.1136/gutjnl-2022-327209 · Cited by 100
Melanoma and microbiota: Current understanding and future directions
Routy, B., Jackson, T., Mählmann, L., Baumgartner, C. K., Blaser, M., Byrd, A., Corvaia, N., Couts, K., Davar, D., Derosa, L., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.003 · Cited by 89
Self-citationGlitza, I. C., Seo, Y. D., Spencer, C. N., Wortman, J. R., Burton, E. M., Alayli, F. A., Loo, C. P., Gautam, S., Damania, A., Densmore, J., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0066 · Cited by 87
“…Ruminococcaceae abundance in this small cohort, we next performed an analysis of response and survival as it related to the relative abundance of Ruminococcaceae at baseline (using the same cutoff of 16% in a previously published cohort of patients with metastatic melanoma treated with ICB (11).”
InfluentialSelf-citationElkrief, A., Pidgeon, R., Vareki, S. M., Messaoudene, M., Castagner, B., & Routy, B. (2025) · Nature reviews. Drug discovery · doi:10.1038/s41573-025-01211-7 · Cited by 88
Lin, A., Xiong, M., Jiang, A., Huang, L., Wong, H. Z. H., Feng, S., Zhang, C., Yu, H., Chen, L., Chi, H., et al. (2025) · iMeta · doi:10.1002/imt2.70070 · Cited by 108
Li, X., Shang, S., Wu, M., Song, Q., & Chen, D. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217096 · Cited by 92
Andreu-Sánchez, S., Blanco-Míguez, A., Wang, D., Golzato, D., Manghi, P., Heidrich, V., Fackelmann, G., Zhernakova, D. V., Kurilshikov, A., Valles-Colomer, M., et al. (2025) · Cell · doi:10.1016/j.cell.2025.04.014 · Cited by 81
Dietary interventions and precision nutrition in cancer therapy
Martínez-Garay, C., & Djouder, N. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.04.004 · Cited by 85
Fecal microbiota transplantation: no longer cinderella in tumour immunotherapy
Yang, Y., An, Y., Dong, Y., Chu, Q., Wei, J., Wang, B., & Cao, H. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.104967 · Cited by 90
Nanomaterials: small particles show huge possibilities for cancer immunotherapy
Chen, Z., Yue, Z., Yang, K., & Li, S. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01692-3 · Cited by 79
Li, W., Zhou, Q., Lv, B., Li, N., Bian, X., Chen, L., Kong, M., Shen, Y., Zheng, W., Zhang, J., et al. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.3c08385 · Cited by 88
The gut microbiome and cancer response to immune checkpoint inhibitors
Gazzaniga, F. S., & Kasper, D. L. (2025) · Journal of Clinical Investigation · doi:10.1172/jci184321 · Cited by 92
The heightened importance of the microbiome in cancer immunotherapy
Villemin, C., Six, A., Neville, B. A., Lawley, T. D., Robinson, M. J., & Bakdash, G. (2023) · Trends in Immunology · doi:10.1016/j.it.2022.11.002 · Cited by 73
Health Benefits of Dietary Fiber for the Management of Inflammatory Bowel Disease
Yusuf, K., Saha, S., & Umar, S. (2022) · Biomedicines · doi:10.3390/biomedicines10061242 · Cited by 88
Faecalibacterium prausnitzii strain EXL01 boosts efficacy of immune checkpoint inhibitors
Bredon, M., Danne, C., Pham, H. P., Ruffié, P., Bessede, A., Rolhion, N., Creusot, L., Brot, L., Alonso, I., Langella, P., et al. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2374954 · Cited by 74
Advances in targeting tumor microenvironment for immunotherapy
Wang, L., Zhang, L., Zhang, Z., Wu, P., Zhang, Y., & Chen, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1472772 · Cited by 110
Self-citationGut microbiome-mediated health effects of fiber and polyphenol-rich dietary interventions
Meiners, F., Ortega-Matienzo, A., Fuellen, G., & Barrantes, I. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1647740 · Cited by 99
Masuda, J., Sakai, H., Tsurutani, J., Tanabe, Y., Masuda, N., Iwasa, T., Takahashi, M., Futamura, M., Matsumoto, K., Aogi, K., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007126 · Cited by 76
Gut microbiota as a new target for anticancer therapy: from mechanism to means of regulation
Sun, J., Song, S., Liu, J., Chen, F., Li, X., & Wu, G. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00678-x · Cited by 89
Penumutchu, S., Korry, B. J., Hewlett, K. K., & Belenky, P. A. (2023) · Nature Communications · doi:10.1038/s41467-023-40553-x · Cited by 75
The gut–liver axis: host microbiota interactions shape hepatocarcinogenesis
Silveira, M. A. D., Bilodeau, S., Greten, T. F., Wang, X. W., & Trinchieri, G. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.02.009 · Cited by 73
Self-citationHilmi, M., Delaye, M., Muzzolini, M., Nicolle, R., Cros, J. F., Hammel, P. R., Cardot‐Ruffino, V., & Neuzillet, C. (2023) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00207-8 · Cited by 82
The role of the gut microbiota in tumor, immunity, and immunotherapy
Xie, Y., & Liu, F. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1410928 · Cited by 77
Metadata
- Authors
- Spencer, C. N., McQuade, J. L., Gopalakrishnan, V., McCulloch, J. A., Vetizou, M., Cogdill, A. P., Khan, M. A. W., Zhang, X., White, M. G., Peterson, C. B., Wong, M. C., Morad, G., Rodgers, T., Badger, J. H., Helmink, B. A., Andrews, M. C., Rodrigues, R. R., Morgun, A., Kim, Y. S., Roszik, J., Hoffman, K. L., Zheng, J., Zhou, Y., Medik, Y. B., Kahn, L. M., Johnson, S., Hudgens, C. W., Wani, K., Gaudreau, P.-O., Harris, A. L., Jamal, M. A., Baruch, E. N., Perez-Guijarro, E., Day, C.-P., Merlino, G., Pazdrak, B., Lochmann, B. S., Szczepaniak-Sloane, R. A., Arora, R., Anderson, J., Zobniw, C. M., Posada, E., Sirmans, E., Simon, J., Haydu, L. E., Burton, E. M., Wang, L., Dang, M., Clise-Dwyer, K., Schneider, S., Chapman, T., Anang, N.-A. A. S., Duncan, S., Toker, J., Malke, J. C., Glitza, I. C., Amaria, R. N., Tawbi, H. A., Diab, A., Wong, M. K., Patel, S. P., Woodman, S. E., Davies, M. A., Ross, M. I., Gershenwald, J. E., Lee, J. E., Hwu, P., Jensen, V., Samuels, Y., Straussman, R., Ajami, N. J., Nelson, K. C., Nezi, L., Petrosino, J. F., Futreal, P. A., Lazar, A. J., Hu, J., Jenq, R. R., Tetzlaff, M. T., Yan, Y., Garrett, W. S., Huttenhower, C., Sharma, P., Watowich, S. S., Allison, J. P., Cohen, L., Trinchieri, G., Daniel, C. R., & Wargo, J. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- National Institutes of Health (US)
- Laboratory of Integrative Cancer Immunology, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892, USA.
- Frederick National Laboratory for Cancer Research (US)
- Oregon State University (US)
- Baylor College of Medicine (US)
- Queen's University (CA)
- The University of Texas Health Science Center at Houston (US)
- Laboratory of Cancer Biology and Genetics, CCR, NCI, NIH, Bethesda, MD 20892, USA.
- Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Harvard University (US)
- Weizmann Institute of Science (IL)
- European Institute of Oncology (IT)
- Columbia University (US)
- University of California, San Francisco (US)
- Broad Institute (US)
- Corresponding author
- Spencer, Christine N.
- McQuade, Jennifer L.
- Gopalakrishnan, Vancheswaran
- McCulloch, John A.
- Cogdill, Alexandria P.
- Cohen, Lorenzo
- Trinchieri, Giorgio
- Daniel, Carrie R.
- Wargo, Jennifer A.
- ORCID
- Spencer, Christine N.
- McQuade, Jennifer L.
- Gopalakrishnan, Vancheswaran
- McCulloch, John A.
- Vetizou, Marie
- Cogdill, Alexandria P.
- Khan, Md A. Wadud
- Zhang, Xiaotao
- White, Michael G.
- Peterson, Christine B.
- Wong, Matthew C.
- Morad, Golnaz
- Rodgers, Theresa
- Badger, Jonathan H.
- Helmink, Beth A.
- Andrews, Miles C.
- Rodrigues, Richard R.
- Morgun, Andrey
- Kim, Young S.
- Roszik, Jason
- Hoffman, Kristi L.
- Zhou, Yifan
- Medik, Yusra B.
- Kahn, Laura M.
- Johnson, Sarah
- Hudgens, Courtney W.
- Wani, Khalida
- Gaudreau, Pierre-Olivier
- Harris, Angela L.
- Jamal, Mohamed A.
- Baruch, Erez N.
- Perez-Guijarro, Eva
- Day, Chi-Ping
- Merlino, Glenn
- Pazdrak, Barbara
- Lochmann, Brooke S.
- Arora, Reetakshi
- Anderson, Jaime
- Zobniw, Chrystia M.
- Simon, Julie
- Haydu, Lauren E.
- Burton, Elizabeth M.
- Wang, Linghua
- Dang, Minghao
- Clise-Dwyer, Karen
- Schneider, Sarah
- Anang, Nana-Ama A. S.
- Toker, Joseph
- Malke, Jared C.
- Glitza, Isabella C.
- Amaria, Rodabe N.
- Tawbi, Hussein A.
- Diab, Adi
- Wong, Michael K.
- Patel, Sapna P.
- Woodman, Scott E.
- Davies, Michael A.
- Ross, Merrick I.
- Gershenwald, Jeffrey E.
- Lee, Jeffrey E.
- Hwu, Patrick
- Jensen, Vanessa
- Samuels, Yardena
- Straussman, Ravid
- Ajami, Nadim J.
- Nelson, Kelly C.
- Nezi, Luigi
- Petrosino, Joseph F.
- Futreal, P. Andrew
- Lazar, Alexander J.
- Hu, Jianhua
- Jenq, Robert R.
- Tetzlaff, Michael T.
- Yan, Yan
- Garrett, Wendy S.
- Huttenhower, Curtis
- Sharma, Padmanee
- Watowich, Stephanie S.
- Allison, James P.
- Cohen, Lorenzo
- Trinchieri, Giorgio
- Daniel, Carrie R.
- Wargo, Jennifer A.
- Venue
- Science
- Published
- 2021-12-24
- Volume
- 374
- Issue
- 6575
- Pages
- 1632-1640
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC8970537
- OpenAlex
- W4200001874
- Cited by
- 966
- References
- 70
- Citations by year
- 2026: 236 · 2025: 216 · 2024: 172 · 2023: 212 · 2022: 130
- FWCI
- 46.90
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Cancer Research UK (27140)
- National Heart, Lung, and Blood Institute (R01HL124112)
- National Cancer Institute (P50CA221703, R01CA219896, F32CA260769, U54CA224070, T32CA009599, R25CA203650, P30CA016672, P30CA013696)
- National Institute of Allergy and Infectious Diseases (R56AI109294, R01AI133822, R01AI143886, R01AI109294)
- National Institute of Environmental Health Sciences (P30ES030285)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Keywords
- dietary fiber, probiotics, gut microbiota, melanoma, immune checkpoint blockade, anti-PD-1 therapy, treatment response, progression-free survival, fecal microbiota, tumor microenvironment, interferon-gamma, cytotoxic T lymphocytes, low-fiber diet
- MeSH terms
- Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Progression-Free Survival, Immune Checkpoint Inhibitors, Animals, Dietary Fiber, Fatty Acids, Volatile, Feces, Female, Humans, Immunotherapy, Male, Melanoma, Melanoma, Experimental, Mice, Inbred C57BL, T-Lymphocytes, Cohort Studies, Probiotics, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.